We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exact Sciences unveiled Cancerguard, a new multi-cancer early detection blood test in the United States.
EXAS' Cancerguard showed 64% sensitivity across cancers and 97.4% specificity to limit false positives.
The company is enrolling 25,000 in the Falcon study to support coverage and future FDA submissions.
Exact Sciences Corporation (EXAS - Free Report) has launched the Cancerguard test, a new multi-cancer early detection (MCED) blood test now offered as a laboratory-developed test (LDT) in the United States. Cancerguard is the first commercially available MCED test of its kind that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often go undiagnosed until later stages when treatment options are limited.
The Cancerguard test is recommended for individuals aged 50-84 with no known cancer diagnosis in the past three years and can be considered annually.
Likely Trend of EXAS Stock Following the News
After the Sept. 10 announcement, EXAS shares rose 2.2%, closing at $56.0 yesterday. The company’s latest introduction represents the culmination of nearly a decade of development and is backed by robust science in partnership with top academic institutions. Over 10 years, use of Exact Sciences’ MCED technology alongside current screening methods could cut stage IV cancer diagnoses by 42% and lower overall cancer-related mortality by 18%. Accordingly, we expect the upward trend in EXAS stock to continue.
Exact Sciences has a market capitalization of $10.37 billion at present. The Zacks Consensus Estimate for the company’s 2025 earnings per share (EPS) stands at 33 cents, a 243.5% improvement over 2024. In the trailing four quarters, it delivered an average earnings surprise of 329.9%.
More on EXAS’ New Cancerguard Test
Nearly 70% of U.S. annual cancer cases and deaths are known to occur in cancers with no recommended screening. According to the company, the Cancerguard test can help address this gap by complementing existing routine screening and extending the reach of early detection. With a simple blood draw, the test detects signals from more than 50 cancer types and subtypes, including some with the highest mortality rates, such as pancreatic, ovarian, liver, esophageal, lung and stomach cancers.
Image Source: Zacks Investment Research
The test is supported by data from robust test-development studies, such as DETECT-A and ASCEND 2, which delivered 68% sensitivity across six of the deadliest cancers and 64% overall sensitivity across a broader range of cancers, excluding breast and prostate. The test also detected more than one-third of stage I or II cancers, demonstrating its ability to detect disease when it is most treatable. By achieving a 97.4% specificity, Cancerguard helps minimize false positives and avoid unnecessary procedures.
Furthermore, the company is actively enrolling up to 25,000 participants in the Falcon Registry Real-World Evidence study to inform future regulatory submissions, support payer discussions on coverage and reimbursement and guide efforts to include the Cancerguard test in clinical guidelines.
To support patient access, Exact Sciences has entered into an agreement with Quest Diagnostics to enable blood collection at the company’s approximately 7,000 patient access sites across the country.
Industry Prospects Favor EXAS
Per a Grand View Research report, the global MCED market is estimated to be worth $1.12 billion in 2025, set to expand at a compound annual growth rate of 17% through 2030. The market’s growth is driven by the rising prevalence of multiple cancers, aided by the growing need to provide efficient methods to detect them at early stages to enable timely, appropriate treatment.
Other Developments at EXAS
Last month, the company announced acquiring exclusive U.S. rights to current and future versions of Freenome’s blood-based, single-indication, colorectal cancer screening tests. The Freenome team recently submitted the last module of the pre-market application to the FDA.
EXAS Stock Price Performance
In the past six months, shares of EXAS have rallied 29.8% compared to the industry’s 1.2% fall.
EXAS’ Zacks Rank and Key Picks
Exact Sciences currently carries a Zacks Rank #3 (Hold).
Masimo shares have jumped 29.6% in the past year. Estimates for the company’s 2025 earnings per share have increased 1.3% to $5.30 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%. In the last reported quarter, it posted an earnings surprise of 8.1%.
Estimates for Phibro Animal Health’s fiscal 2026 earnings per share have increased 6.5% to $2.45 in the past 30 days. Shares of the company have surged 87.3% in the past year compared with the industry’s flat growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%. In the last reported quarter, it delivered an earnings surprise of 9.6%.
Estimates for Envista’s 2025 earnings per share have remained constant at $1.12 in the past 30 days. Shares of the company have rallied 11.3% in the past year compared with the industry’s flat growth. Its earnings yield of 5.4% also outpaced the industry’s 0.2% yield. NVST’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs
Key Takeaways
Exact Sciences Corporation (EXAS - Free Report) has launched the Cancerguard test, a new multi-cancer early detection (MCED) blood test now offered as a laboratory-developed test (LDT) in the United States. Cancerguard is the first commercially available MCED test of its kind that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often go undiagnosed until later stages when treatment options are limited.
The Cancerguard test is recommended for individuals aged 50-84 with no known cancer diagnosis in the past three years and can be considered annually.
Likely Trend of EXAS Stock Following the News
After the Sept. 10 announcement, EXAS shares rose 2.2%, closing at $56.0 yesterday. The company’s latest introduction represents the culmination of nearly a decade of development and is backed by robust science in partnership with top academic institutions. Over 10 years, use of Exact Sciences’ MCED technology alongside current screening methods could cut stage IV cancer diagnoses by 42% and lower overall cancer-related mortality by 18%. Accordingly, we expect the upward trend in EXAS stock to continue.
Exact Sciences has a market capitalization of $10.37 billion at present. The Zacks Consensus Estimate for the company’s 2025 earnings per share (EPS) stands at 33 cents, a 243.5% improvement over 2024. In the trailing four quarters, it delivered an average earnings surprise of 329.9%.
More on EXAS’ New Cancerguard Test
Nearly 70% of U.S. annual cancer cases and deaths are known to occur in cancers with no recommended screening. According to the company, the Cancerguard test can help address this gap by complementing existing routine screening and extending the reach of early detection. With a simple blood draw, the test detects signals from more than 50 cancer types and subtypes, including some with the highest mortality rates, such as pancreatic, ovarian, liver, esophageal, lung and stomach cancers.
Image Source: Zacks Investment Research
The test is supported by data from robust test-development studies, such as DETECT-A and ASCEND 2, which delivered 68% sensitivity across six of the deadliest cancers and 64% overall sensitivity across a broader range of cancers, excluding breast and prostate. The test also detected more than one-third of stage I or II cancers, demonstrating its ability to detect disease when it is most treatable. By achieving a 97.4% specificity, Cancerguard helps minimize false positives and avoid unnecessary procedures.
Furthermore, the company is actively enrolling up to 25,000 participants in the Falcon Registry Real-World Evidence study to inform future regulatory submissions, support payer discussions on coverage and reimbursement and guide efforts to include the Cancerguard test in clinical guidelines.
To support patient access, Exact Sciences has entered into an agreement with Quest Diagnostics to enable blood collection at the company’s approximately 7,000 patient access sites across the country.
Industry Prospects Favor EXAS
Per a Grand View Research report, the global MCED market is estimated to be worth $1.12 billion in 2025, set to expand at a compound annual growth rate of 17% through 2030. The market’s growth is driven by the rising prevalence of multiple cancers, aided by the growing need to provide efficient methods to detect them at early stages to enable timely, appropriate treatment.
Other Developments at EXAS
Last month, the company announced acquiring exclusive U.S. rights to current and future versions of Freenome’s blood-based, single-indication, colorectal cancer screening tests. The Freenome team recently submitted the last module of the pre-market application to the FDA.
EXAS Stock Price Performance
In the past six months, shares of EXAS have rallied 29.8% compared to the industry’s 1.2% fall.
EXAS’ Zacks Rank and Key Picks
Exact Sciences currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space include Masimo (MASI - Free Report) , Phibro Animal Health (PAHC - Free Report) and Envista (NVST - Free Report) . While Masimo sports a Zacks Rank #1 (Strong Buy), Phibro and Envista each carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo shares have jumped 29.6% in the past year. Estimates for the company’s 2025 earnings per share have increased 1.3% to $5.30 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%. In the last reported quarter, it posted an earnings surprise of 8.1%.
Estimates for Phibro Animal Health’s fiscal 2026 earnings per share have increased 6.5% to $2.45 in the past 30 days. Shares of the company have surged 87.3% in the past year compared with the industry’s flat growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%. In the last reported quarter, it delivered an earnings surprise of 9.6%.
Estimates for Envista’s 2025 earnings per share have remained constant at $1.12 in the past 30 days. Shares of the company have rallied 11.3% in the past year compared with the industry’s flat growth. Its earnings yield of 5.4% also outpaced the industry’s 0.2% yield. NVST’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.5%.